Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
| Price | $31.91 |
|---|---|
| Market cap | $1.41B |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| 52-week range | 24.15-40.17 |
| Beta | -1.13 |
Explore AVLN's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.